Trial Profile
Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2014
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Cognition disorders
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 16 Oct 2014 New trial record